Your browser doesn't support javascript.
loading
First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma.
Banihashemian, Seyedeh Somayyeh; Bayat, Mohadese; Pirayesh, Elahe; Divband, Ghasemali; Abolhosseini, Abdolghafar; Akbari, Mohammad Esmaeel.
Afiliação
  • Banihashemian SS; From the Cancer Research Center, Shahid Beheshti University of Medical Sciences.
  • Bayat M; Department of Nuclear Medicine, Shohada Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences.
  • Pirayesh E; Department of Nuclear Medicine, Shohada Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences.
  • Divband G; Khatam PET-CT Center, Khatam-al-Anbia Hospital.
  • Abolhosseini A; Parsisitope Company, Tehran, Iran.
  • Akbari ME; From the Cancer Research Center, Shahid Beheshti University of Medical Sciences.
Clin Nucl Med ; 49(7): e334-e337, 2024 Jul 01.
Article em En | MEDLINE | ID: mdl-38831513
ABSTRACT
ABSTRACT Fibroblast activation protein (FAP) is a new promising molecular target for theragnostic approach. FAP inhibitors (FAPIs) labeled with 177Lu could be potentially a therapeutic radiopharmaceutical. Here, we presented the experience of 4 cycles of 177Lu-FAPI in a 67-year-old man with an unresectable mediastinal sarcoma.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias do Mediastino Limite: Aged / Humans / Male Idioma: En Revista: Clin Nucl Med Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias do Mediastino Limite: Aged / Humans / Male Idioma: En Revista: Clin Nucl Med Ano de publicação: 2024 Tipo de documento: Article